New drug tarlatamab takes on tough lung cancers
NCT ID NCT07016230
First seen Jun 26, 2026 · Last updated Aug 05, 2026 · Updated 3 times
Summary
This phase 2 trial is testing a drug called tarlatamab in 40 people with advanced small-cell lung cancer or other poorly differentiated neuroendocrine cancers. The drug is given by IV and aims to shrink tumors. Researchers will also study blood and tumor samples to understand why some patients respond and others don't.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tarlatamab
- What this could lead to
- If successful, this could provide a new treatment option for hard-to-treat small-cell lung cancer and related neuroendocrine cancers.
- What could go wrong
- This is a small, early-phase trial with only 40 participants. The drug may not shrink tumors or could cause serious side effects. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC/LOCALLY ADVANCED HIGH-GRADE MTC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gustave Roussy
Villejuif, France